Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception
Open accessAbstract
Cannabinoids and opiates inhibit pain, in part, by activating the periaqueductal gray (PAG). Evidence suggests this activation occurs through distinct mechanisms. If the antinociceptive mechanisms are distinct, then cross-tolerance between opioids and cannabinoids should not develop. This hypothesis was tested by measuring the antinociceptive effect of microinjecting morphine into the ventrolateral PAG of rats pretreated with the cannabinoid HU-210 for two days. Male Sprague-Dawley rats were injected twice a day for two days with vehicle (0.4 microL), morphine (5 microg/0.4 microL), HU-210 (5 microg/0.4 microL), or morphine combined with HU-210 into the ventrolateral PAG. Repeated injections of morphine caused a rightward shift in the morphine dose-response curve on Day 3 (i.e., tolerance developed). No tolerance was evident in rats pretreated with morphine combined with HU-210. In rats pretreated with HU-210 alone, morphine antinociception was enhanced. This enhancement was blocked by pretreating rats with the cannabinoid receptor antagonist AM-251, and it also disappeared when rats were tested one week later. Acute microinjection of HU-210 into the PAG antagonized morphine antinociception, suggesting that HU-210-induced enhancement of morphine antinociception is a compensatory response. As hypothesized, there was no evidence of cross-tolerance between morphine and HU-210. In fact, cannabinoid pretreatment enhanced the antinociceptive effect of microinjecting morphine into the ventrolateral PAG. These findings suggest that alternating opioid and cannabinoid treatment could be therapeutically advantageous by preventing the development of tolerance and enhancing morphine antinociception.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
No evidence of synergism was found for morphine plus HU-210; the combination showed the greatest increase in hot plate latency (39.9 s ± 1.1 s), but was not significantly different from morphine alone.
“No evidence of synergism.Morphine + HU-210 showed the greatest increase in hot plate latency (39.9 s ± 1.1 s), but was not significantly different from morphine alone”
From Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis (2017) · cites this paper as Wilson 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 68 · Cited by 52
- Authors
- Wilson, A. R., Maher, L., & Morgan, M. M.
- Affiliations
- Washington State University Vancouver (US)
- Corresponding author
- Morgan, Michael M.
- ORCID
- Morgan, Michael M.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2008-12
- Volume
- 55
- Issue
- 7
- Pages
- 1219-1225
- ISSN
- 0028-3908 (ISSN-L)
- PMC
- PMC2743428
- OpenAlex
- W1979139982
- Cited by
- 52
- References
- 68
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 7 · 2019: 1 · 2018: 5 · 2017: 3 · 2015: 4 · 2014: 1 · 2013: 1 · 2012: 5
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (DA015498, R01DA015498)
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- periaqueductal gray, morphine, cannabinoids, HU-210, opioid tolerance, cross-tolerance, antinociception, pain modulation, AM251, cannabinoid receptor antagonism, ventrolateral periaqueductal gray, opioid-cannabinoid interaction
- MeSH terms
- Analgesics, Opioid, Animals, Behavior, Animal, Cannabinoids, Data Interpretation, Statistical, Dose-Response Relationship, Drug, Drug Synergism, Male, Microinjections, Morphine, Motor Activity, Pain Measurement, Periaqueductal Gray, Dronabinol, Rats, Sprague-Dawley, Neuroprotective Agents, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
